Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia ROCKAWAY, N.J. , Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) “NOVIS” Clinical Trial (n=150) of nVNS for the acute treatment of Ischemic Stroke will complete recruitment in 2023 ROCKAWAY, N.J. , Oct.
BASKING RIDGE, N.J. , July 16, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 14, 2020 , the company’s cash was incorrectly stated as being as of the end of the first quarter. Note that the company ended the second quarter of 2020 with cash, cash equivalents and
ROCKAWAY, N.J. --(BUSINESS WIRE)--Mar. 15, 2021-- Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC . Peter Staats , M.D. Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symptoms and at-home steps that can be discussed with